BBIO — BRIDGEBIO PHARMA INC

Ownership history in VIKING GLOBAL INVESTORS LP  ·  27 quarters on record

This page tracks every 13F SEC filing in which VIKING GLOBAL INVESTORS LP reported a position in BRIDGEBIO PHARMA INC (BBIO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
5.21% (2020 Q4)
Avg. % of fund
2.82%
First filed
2019 Q2
Last filed
2025 Q4
Quarters held
27
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 14,393,934 -1,583,915 -9.9% 2.92% $1.10B $76.49
2025 Q3 REDUCED 15,977,849 -2,577,526 -13.9% 2.16% $829.9M $51.94
2025 Q2 REDUCED 18,555,375 -3,500,000 -15.9% 2.32% $801.2M $43.18
2025 Q1 REDUCED 22,055,375 -3,065,616 -12.2% 2.42% $762.5M $34.57
23 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    BBIO price (monthly, adj. close)

Other funds also holding BBIO

As of 2025 Q4 — sorted by position size

Aisling Capital Management LP 3Y 7Y 81.29% Kohlberg Kravis Roberts & Co. L.P. 3Y 7Y 16.22% Frazier Life Sciences Management, L.P. 3Y 7.28% First Turn Management, LLC 5.2% BOONE CAPITAL MANAGEMENT LLC 3Y 4.44% Eagle Health Investments LP 3Y 4.36% Monashee Investment Management LLC 3Y 7Y 4.31% Cormorant Asset Management, LP 3Y 7Y 4.24% Atle Fund Management AB 3Y 7Y 3.45% Laurion Capital Management LP 3Y 7Y 3.28%
← Back to VIKING GLOBAL INVESTORS LP Holdings